BioCardia and CellProthera extend partnership agreement

BioCardia and CellProthera, a private developer of cell-based therapies to repair ischemic tissues, announce an amendment to their Clinical Research Supply and Support Agreement. The amendment extends the long-term partnership between both organizations. The agreement relates to CellProthera’s use of BioCardia’s Helix transendocardial biotherapeutic delivery system for its ongoing Phase I/IIb EXCELLENT study of its lead product candidate ProtheraCytes. CellProthera has developed ProtheraCytes as a one shot minimally invasive autologous ATMP cell therapy to improve the quality of life of post-Acute Myocardial Infarction patients who have no therapeutic solution to restore the heart’s function, and to reduce ongoing hospitalizations and invasive medical treatments such as heart transplants. CellProthera and BioCardia have extended the agreement to complete the ongoing Phase I/IIb EXCELLENT study. The agreement incorporates the intention for both organizations to work together regarding CellProthera’s next clinical study, potential early access commercialization, which could begin in 2024, and future full commercialization programs.